Our mission is to address unmet medical needs by developing novel immunotherapies against medically-relevant targets irrespective of their location (i.e. extracellular, intracellular, or membrane-bound antigens) utilizing Sorrento’s unique portfolio of proprietary OnTarget antibody technologies.

Sorrento is an antibody-centric, clinical stage biopharmaceutical company focused on the discovery and development of safe and effective immunotherapies for oncology and autoimmune/inflammation diseases. Sorrento’s lead programs consist of four Phase III BioSimilar/BioBetter antibodies, which address an established market of more than $13 billion, and two Phase I CAR-T programs for treatment of solid tumors. Sorrento also is advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs). Sorrento partnered with City of Hope to form LA Cell subsidiary to focus on developing cell-internalizing mAbs against undruggable intracellular targets.

“We believe our unique portfolio of OnTarget immunotherapies is unrivaled in the industry. It includes intracellular antibodies, immune checkpoint inhibitors, bispecific antibodies, antibody-drug conjugates (ADCs) as well as chimeric antigen receptor (CAR)-based cellular therapies.”
– CEO Dr. Henry Ji